Neurocrine logo

NeurocrineNBIX

NASDAQ

生物科技

US$150.02-5.05%

NBIX 暫無 AI 快取快照。

成為第一個對該股票執行多智能體分析的使用者。

關鍵指標

$13.10B市值
US$160.1852 週最高
US$104.7352 週最低
1,103,20430 日均量

2,000 員工數100.58M 流通股本上市日期 1996-05-23

下次財報 ~2026年5月5日

關於 Neurocrine

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

最新新聞

展示全市場股票新聞

相關股票生物科技 產業

想看 NBIX 的即時 AI 觀點嗎?

啟動即時多智能體分析室 — Claude、GPT、Gemini、DeepSeek、Grok 和 Qwen 同時分析 NBIX,即時輸出訊號。

Neurocrine (NBIX) 還能買嗎? 多智能體 AI 即時分析